BlossomHill Therapeutics
PublicBlossomHill Therapeutics is now publicly traded
The data on this page reflects BlossomHill Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series B
Extension
Dec 10, 2025
Total Funding Raised
$345.65M
Company Overview
BlossomHill Therapeutics operates in Healthcare and is based in San Diego, California. It has raised $345.65M.
BlossomHill Therapeutics is a biopharmaceutical company that discovers and develops small molecule medicines for the treatment of high-need cancers and autoimmune diseases.
Sector
Healthcare
Verticals
Life Sciences, Oncology
AI Layer
Non-AI
BlossomHill Therapeutics Comparables
Compare BlossomHill Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ArriVent | 85% | |
| Black Diamond Therapeutics | 84% | |
| Allorion Therapeutics | 84% |
For institutional investors. Book with your work email.
BlossomHill Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Dec 10, 2025 | ||||
| Series B | Feb 29, 2024 | ||||
| Series B | Dec 28, 2023 | ||||
| Series A | Mar 3, 2021 | ||||
| Private Placement | Dec 31, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BlossomHill Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioTrack Capital | Series B Extension |
| Janus Henderson Group | Series B Extension |
| H&D Asset Management | Series B |
| Cormorant Asset Management | Series B, Series B Extension, Series A |
| OrbiMed | Series B, Series B Extension, Series A |
| Brahma Capital | Series B Extension |
| Plaisance Capital Management | Series B |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 22, 2026
BlossomHill Therapeutics, Inc. announces a collaboration with Foundation Medicine to develop and validate a companion diagnostic assay (CDx) for the EGFR C797S resistance mutation, using the ongoing Phase 1/2 SOLARA trial evaluating BH-30643 in EGFR-mutant non-small cell lung cancer patients in California on Oct 22nd '26.
- partners_withOct 22, 2026
BlossomHill Therapeutics, Inc. and Foundation Medicine, Inc. partner to develop and validate a companion diagnostic assay for the EGFR C797S resistance mutation, leveraging the Phase 1/2 SOLARA trial of BH-30643 in EGFR-mutant non-small cell lung cancer, in California on Oct 22nd '26.
For institutional investors. Book with your work email.
BlossomHill Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.